Recent Advancements in Psoriasis Treatment
These pages are often referring to the rapidly advancing therapeutic range available for the treatment of moderate to severe psoriasis. A report delivered at this year’s American Academy of Dermatology scientific meeting in San Francisco showed that a new biological drug was better than the current drug ustekinumab (Stelara, Janssen) in treating psoriasis.
The new biological drug targets interleukin-23 (IL-23) as opposed to ustekinumab which targets both IL-23 and IL-12. The new drug (name yet to be to bring about clear or almost clear skin (77% vs 40%). Phase III clinical trials are planned for the near future.
If you are suffering with psoriasis, get in touch and let our consultant dermatologists treat your disease.Another new drug, apremilast (Otezla,Celgene), a phosphodiesterase inhibitor already approved by the FDA for treatment of psoriatic arthritis, was also shown to be effective in psoriasis. The data presented at the American Academy of Dermatology scientific meeting in San Francisco this month, showed that apremilast given as an oral tablet was as effective at producing a ‘statistically significant and clinically meaningful improvement’ in psoriasis as the biological drug etanercept.
